Showing 761 - 780 results of 32,373 for search '(( 50 ((a decrease) OR (mean decrease)) ) OR ( 5 ((fold decrease) OR (nn decrease)) ))', query time: 0.83s Refine Results
  1. 761
  2. 762

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  3. 763

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  4. 764

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  5. 765

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
  6. 766
  7. 767
  8. 768
  9. 769
  10. 770
  11. 771
  12. 772
  13. 773
  14. 774
  15. 775
  16. 776

    Fold decrease in virulence gene expression of <i>Salmonella in vivo</i> and <i>in vitro</i><sup>a</sup>. by Xiaojian Yang (295141)

    Published 2014
    “…Values represent down-regulation (fold-decrease) of gene expression except for the value in bold that was up-regulated (fold-increase).…”
  17. 777

    Complete data. by Jan Víteček (11434774)

    Published 2024
    “…A tenfold decrease or increase in concentration induced only a 2-fold decrease or increase in clot degradation. …”
  18. 778

    Fig 4 - by Jan Víteček (11434774)

    Published 2024
    “…A tenfold decrease or increase in concentration induced only a 2-fold decrease or increase in clot degradation. …”
  19. 779

    Exposure to EtBr decreases mtRNA in rat striatal co-cultures, purified neuronal cultures, and astrocytes. by Emily Booth Warren (4276333)

    Published 2017
    “…<p>(A-C) Log2-fold decrease in mtRNA expression after EtBr treatment assayed with RNASeq, in (A) NECos, (B), pure neuronal cultures, and (C) astrocytes. …”
  20. 780

    The mean <i>z</i>-coordinate error decreasing percentages (%) of SSI-RIK compared to EM-SFM, CSF and RIK, when the sequence sizes vary from 15 to 50 with an equal interval 5. by Ya-Ping Wang (44525)

    Published 2015
    “…<p>The mean <i>z</i>-coordinate error decreasing percentages (%) of SSI-RIK compared to EM-SFM, CSF and RIK, when the sequence sizes vary from 15 to 50 with an equal interval 5.…”